Loading…
Bright Minds Biosciences Inc. is projected to rise to $92.90 by 2027, a +27% move from its current price of $73.26. DRUG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $71.11 | $73.30 | $75.56 | +0.06% |
| Aug 3 | $70.26 | $73.35 | $76.57 | +0.12% |
| Aug 4 | $69.63 | $73.39 | $77.35 | +0.18% |
| Aug 5 | $69.11 | $73.43 | $78.03 | +0.24% |
| Aug 6 | $68.66 | $73.48 | $78.64 | +0.30% |
| Aug 7 | $68.25 | $73.52 | $79.20 | +0.36% |
| Aug 8 | $67.89 | $73.57 | $79.72 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $67.89 | $73.57 | $79.72 | +0.42% |
| Week 2 | $65.94 | $73.87 | $82.76 | +0.84% |
| Week 3 | $64.55 | $74.18 | $85.25 | +1.26% |
| Week 4 | $63.43 | $74.49 | $87.47 | +1.68% |
| Week 5 | $62.50 | $74.80 | $89.52 | +2.10% |
| Week 6 | $61.70 | $75.11 | $91.45 | +2.53% |
| Week 7 | $60.99 | $75.43 | $93.29 | +2.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bright Minds Biosciences Inc. is a biotechnology company focused on developing therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Bright Minds also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. The company has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study.
The company was founded in 2017 and is headquartered in New York, New York.
Bright Minds Biosciences Inc. (DRUG) is currently priced at $71.29. The stock is positioned in the market with a current price of $71.29 and a ranking of 2732 by market cap. Its market capitalization stands at $699.5M.
The 2026 forecast shows an average price of $71.29 with a min of $59.17 and a max of $102.69, and a neutral sentiment. The thirty-day price range is $56.88 to $89.35, reflecting near-term volatility within a defined band.
A major floor 27.4% below — a decisive break under it would weaken the trend.
The nearest floor, 17.2% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 23.9% above — clearing it would confirm fresh momentum.
Key DRUG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRUG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $72.56 | Buy | $73.02 | Buy |
| MA 10 | $73.28 | Sell | $73.05 | Buy |
| MA 20 | $73.31 | Sell | $72.59 | Buy |
| MA 50 | $71.93 | Buy | $73.16 | Buy |
| MA 100 | $76.31 | Sell | $74.36 | Sell |
| MA 200 | $75.71 | Sell | $70.48 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.62 | Neutral |
| Stoch RSI (14) | 36.71 | Neutral |
| CCI (20) | -1.25 | Neutral |
| Williams %R (14) | -64.69 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -3.50 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 35.31 | Neutral |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | 3.03 | Buy |
| Ultimate (7,14,28) | 43.70 | Neutral |
| Momentum (10) | -2.86 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 72.76 | Buy |
| ADX (14) | 11.40 | Neutral |
| ATR (14) | 1.97 | Info |
The near-term picture is bullish, with RSI14 at 50 and a bullish sentiment. The stock is trading around the 50-day moving average of $72.72, below the 200-day moving average of $75.27. Support is indicated at $59.17 and resistance at $78.20.
The 30-day range spans from $56.88 to $89.35, highlighting potential movement within that window. The near-term volatility is high, as shown by an annualized volatility of 70.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $59.17 | $73.26 | $102.97 | 0% | Neutral | |
| $73.33 | $92.90 | $124.87 | +27% | Bullish | |
| $75.69 | $98.97 | $138.63 | +35% | Bullish | |
| $85.65 | $114.99 | $166.28 | +57% | Bullish | |
| $114.75 | $157.69 | $234.21 | +115% | Bullish | |
| $128.81 | $180.81 | $274.85 | +147% | Bullish | |
| $139.94 | $200.36 | $310.96 | +173% | Bullish | |
| $153.87 | $224.43 | $354.92 | +206% | Bullish | |
| $150.41 | $223.30 | $359.28 | +205% | Bullish | |
| $168.09 | $253.81 | $414.94 | +246% | Bullish | |
| $241.95 | $394.74 | $689.83 | +439% | Bullish | |
| $551.15 | $1,029.25 | $1,980.91 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $59.17 | $73.26 | $90.17 | +0.00% |
| September 2026 | $65.35 | $77.57 | $94.88 | +5.89% |
| October 2026 | $64.67 | $77.34 | $95.72 | -0.30% |
| November 2026 | $64.75 | $77.92 | $97.35 | +0.74% |
| December 2026 | $67.52 | $81.72 | $102.97 | +4.88% |
Click any year to see its month-by-month DRUG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DRUG to range from $59.17 to $102.97 through 2026. The $73.26 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DRUG price prediction for 2027 points to an average of $92.90 (low $73.33, high $124.87) — a potential gain of +27% on today's $73.26. Momentum favours further upside here.
In 2028, DRUG is projected to trade between $75.69 and $138.63, averaging $98.97 — a potential gain of +35% from today's $73.26. That is up +7% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Bright Minds Biosciences Inc.'s 2029 outlook centres on $114.99, within a $85.65 to $166.28 range. That is up +16% on the projected 2028 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2030, DRUG could reach as high as $234.21, with a base case around $157.69 and support toward $114.75 — roughly +115% from $73.26. Buyers look set to stay in control over this stretch.
Expect DRUG to range from $128.81 to $274.85 through 2031. The $180.81 average target implies a +147% move from current prices. That is up +15% on the projected 2030 average. Momentum favours further upside here.
The DRUG price prediction for 2032 points to an average of $200.36 (low $139.94, high $310.96) — a potential gain of +173% on today's $73.26. Buyers look set to stay in control over this stretch.
In 2033, DRUG is projected to trade between $153.87 and $354.92, averaging $224.43 — a potential gain of +206% from today's $73.26. That is up +12% on the projected 2032 average. Momentum favours further upside here.
Bright Minds Biosciences Inc.'s 2034 outlook centres on $223.30, within a $150.41 to $359.28 range. That is -1% versus the projected 2033 average. That marks a +205% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DRUG could reach as high as $414.94, with a base case around $253.81 and support toward $168.09 — roughly +246% from $73.26. Momentum favours further upside here.
Expect DRUG to range from $241.95 to $689.83 through 2040. The $394.74 average target implies a +439% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DRUG price prediction for 2050 points to an average of $1,029.25 (low $551.15, high $1,980.91) — a potential gain of +13.0x on today's $73.26. Momentum favours further upside here.
Investing $1,000 in DRUG today (≈ 13.650014 DRUG) could be worth
$14,049.28
+$13,049.28 (+1305%) by 2050 · US Dollar
Based on the average projected DRUG price of $1,029.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRUGwould be worth at today's price.
$1,000 invested in DRUG on Jul 31, 2025 (≈ 29.612081 DRUG) would be worth
$2,169.38
+$1,169.38 (+116.9%) today · 2.17× · US Dollar
Based on a DRUG entry price of $33.77 vs. today's $73.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.33 | $1,027.06 | +2.7% |
| 1 month ago | $66.54 | $1,100.99 | +10.1% |
| 3 months ago | $86.96 | $842.46 | -15.8% |
| 6 months ago | $78.64 | $931.59 | -6.8% |
| 1 year ago | $33.77 | $2,169.38 | +116.9% |
| All time (5.0y) ago | $26.1 | $2,806.9 | +180.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRUG forecast.
Our base-case forecast reaches $150.00 around 2030.
Implied market cap at $150.00: $1.47B
The multi-year forecast shows strong upside potential, with the 2026 average at $71.29 and a neutral sentiment. In 2027 the average is projected at $88.19 with a max of $120.77 and ROI of 23.7%, marked as bullish. In 2028 the average is $94.23 (min $70.74, max $135.00) with ROI 32.2% and bullish sentiment, followed by 2029 with an average of $109.37 (min $79.66, max $162.28) and ROI 53.4%.
The forecast accelerates to 2030 with an average of $149.43 (min $105.96, max $228.29) and ROI 109.6%, then to 2031 with an average of $172.84 (min $119.59, max $270.85) ROI 142.4%, and higher through 2032–2035. By 2040 the average reaches $360.67 (min $209.12, max $657.60) with ROI 405.9% and bullish sentiment, and by 2050 the average is $957.98 (min $471.79, max $1,937.88) with ROI 1243.8%, also bullish. These figures represent estimates, not guarantees, and are subject to uncertainty and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $149.43 with a min of $105.96 and a max of $228.29, and an ROI of 109.6%. The sentiment is BULLISH.
Forecasts show rising averages and bullish sentiment from 2027 onward, with ROIs of 23.7% in 2027, 32.2% in 2028, 53.4% in 2029, and 109.6% in 2030, culminating in even higher ROIs in later years. These are estimates, not guarantees.
According to the forecast, the 2028 max price is $135.00, with the 2027 max at $120.77 and the 2026 max at $102.69.
Current price is $71.29 and the market capitalization is $699.5M. The stock ranks 2732 by market cap.
RSI14 is 50 and the sentiment is BULLISH. The 50-day moving average is $72.72 and the 200-day moving average is $75.27. Support is at $59.17 and resistance at $78.20. The 30-day range is $56.88 to $89.35, and annualized volatility is 70.
Bright Minds Biosciences Inc. Community Discussion
0Share your Bright Minds Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.